@article{11144dc78b574ead93780ca8dde11997,
title = "Prostate cancer, version 1.2021: Featured updates to the nccn guidelines",
abstract = "The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.",
author = "Edward Schaeffer and Sandy Srinivas and Antonarakis, {Emmanuel S.} and Armstrong, {Andrew J.} and Bekelman, {Justin E.} and Heather Cheng and D'Amico, {Anthony Victor} and Davis, {Brian J.} and Neil Desai and Tanya Dorff and Eastham, {James A.} and Farrington, {Thomas A.} and Xin Gao and Horwitz, {Eric Mark} and Ippolito, {Joseph E.} and Kuettel, {Michael R.} and Lang, {Joshua M.} and Rana McKay and Jesse McKenney and George Netto and Penson, {David F.} and Pow-Sang, {Julio M.} and Robert Reiter and Sylvia Richey and Mack Roach and Stan Rosenfeld and Ahmad Shabsigh and Spratt, {Daniel E.} and Teply, {Benjamin A.} and Jonathan Tward and Shead, {Dorothy A.} and Freedman-Cass, {Deborah A.}",
note = "Funding Information: This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie. Publisher Copyright: {\textcopyright} 2021 Harborside Press. All rights reserved.",
year = "2021",
month = feb,
day = "2",
doi = "10.6004/jnccn.2021.0008",
language = "English (US)",
volume = "19",
pages = "134--143",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",
}
